AutoImmune-AIMM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AutoImmune-AIMM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Daniel Goncharoff who wrote (15)	3/5/1997 12:30:00 PM
From: Thomas Stewart	of 298

Has anyone tried to value this stock assuming that the trials for MS are successful? About 250 thousand in the US alone are afflicted with MS. I assume that half of them at least, those afflicted with relapsing remitting MS, the type of MS that is being considered in this study, will begin antigen-feeding with Myloral, even if they continue with other therapies. I also assume that they will need to continue taking Myloral indefinately. But what can AIMM charge for this stuff? And, more importantly, how will that affect the price of the stock? The key question as far as I am concerned is how much they will charge for this therapy. Can anyone help to evaluate the market for Myloral and take a guess on its price? Thanks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next